News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase II
Avexxin Completes Phase I/IIA Study In Psoriasis And Achieves Proof-Of-Concept In Man With Its Compound AVX001 In A Topical Formulation 7/2/2015
Cyclacel Pharmaceuticals, Inc. (CYCC) Release: First Patient Dosed In IST Of CDK Inhibitor Seliciclib In Cushing's Disease, A Serious Endocrine Disorder 7/2/2015
EXCLUSIVE: Pediatric Patients Could Benefit Most From New Oncoceutics Cancer Drug, Says Exec 7/2/2015
Evotec AG (EVTG.F), Roche (RHHBY)'s Alzheimer's Hopeful Fails Another Trial 7/1/2015
TetraLogic Pharmaceuticals (TLOG) Announces Update On MDS Clinical Program 7/1/2015
Teva (TEVA) And Xenon Pharmaceuticals Inc. Provide Update On TV-45070 Phase IIb Study In Osteoarthritis Pain 7/1/2015
VistaGen Therapeutics, Inc. Receives FDA And NIH Clearance To Initiate NIH-Funded Phase 2 Study Of Orally Active AV-101 In Major Depressive Disorder 7/1/2015
Replicel Life Sciences Enrolls First Participant In Phase 1/2 Clinical Trial Of RCT-01 For Chronic Achilles Tendinosis 6/30/2015
Anavex (AVXL) To Present Initial Clinical Data From The Phase IIa Clinical Trial Of ANAVEX 2-73 At The Alzheimer’s Association International Conference (AAIC) 6/30/2015
Oramed Pharmaceuticals Inc. (ORMP) Submits Protocol To U.S. FDA For Its Phase Ilb Oral Insulin Study 6/30/2015
Oramed Pharmaceuticals Inc. (ORMP) Enrolls First Patient In Its Phase Ilb Oral Insulin Study 6/30/2015
BiondVax Pharmaceuticals Presents BVX-006 Preliminary Phase II Results: The Universal Flu Vaccine At Higher Doses Is Safe And Improves Immunogenicity In Older Adults 6/30/2015
Pharma Two B Ltd. Announces Positive Results In Its Phase Ilb Pivotal Clinical Study Of P2B001 For The Treatment Of Early Stage Parkinson's Disease 6/30/2015
Vitae Pharma (VTAE)’ Diabetes Drug Fails Mid-Stage Trial, the Second Drug in Less Than Six Months to Fail 6/29/2015
Vitae Pharma (VTAE) Announces Top-Line Results From Metformin Arm of Ongoing Phase II Clinical Trial of BI187004/VTP-34072 in Overweight Type 2 Diabetics 6/29/2015
Synthetic Biologics, Inc. (SYN)' Initiates SYN-010 Phase 2 Clinical Trial To Treat Irritable Bowel Syndrome With Constipation (IBS-C) 6/29/2015
Aratana Therapeutics (PETX) Announces Positive Pivotal Results For AT-002 6/29/2015
Galectin Therapeutics Initiates Enrollment For GR-MD-02 Phase II Clinical Trial In NASH With Cirrhosis 6/29/2015
Aduro Biotech (ADRO) Announces Immunotherapy Regimen Successfully Passes Futility Analysis In Phase IIb ECLIPSE Trial In Metastatic Pancreatic Cancer 6/29/2015
BioBlast Pharma (ORPN) Receives Orphan Drug Designation From The European Commission (EC) For Cabaletta For The Treatment Of Spinocerebellar Ataxia (SCA) 6/29/2015
IND For Phase 1b/2 Ovarian Cancer Trial Transferred To Prescient Therapeutics 6/29/2015
Invion Limited Completes Dosing In Key Phase II Clinical Trial Of Oral INV102 (Nadolol) In Smoking Cessation 6/29/2015
StemCells (STEM) Reports Top Line Results For Its Phase I/II Study In Dry Age Related Macular Degeneration 6/26/2015
PledPharma Presents Additional Results From A Phase IIb Study With Pledox At The Scientific Conference MASCC 6/26/2015
Immune Pharmaceuticals, Inc. Initiates Phase II Clinical Trials With Bertilimumab In Ulcerative Colitis And Bullous Pemphigoid 6/26/2015
Aquinox (AQXP)’s Bladder Pain Drug Fails to Meet Statistical Endpoint in Phase II Trial 6/25/2015
Derma Sciences, Inc. (DSCI) Announces Publication In Advances In Wound Care 6/25/2015
Hemostemix Enrolls Fifth Participant At Vancouver General Hospital In International Phase-2 Clinical Trial For Critical Limb Ischemia 6/25/2015
Conatus Pharma Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial Of Emricasan Confirming Activity Of Relevant Mechanisms And Opportunity For Histological Improvement 6/25/2015
Vical  (VICL) Herpes Vaccine Clinical Trial Disappoints with "Confounding Results" 6/24/2015
Alcobra (ADHD)’s Fragile X Syndrome Drug Fails During Mid-Stage Trial 6/24/2015
Transition Therapeutics Inc. (TTH.TO) Announces Results Of Clinical Study Of ELND005 In Agitation And Aggression In Patients With Alzheimer's Disease 6/24/2015
Vanda Pharmaceuticals, Inc. (VNDA) Announces Positive Results From The Relapse Prevention Study In Patients With Schizophrenia (REPRIEVE) Demonstrating The Long-Term Maintenance Effects Of Fanapt (iloperidone) 6/24/2015
Vaccinex, Inc. Announces The Initiation Of A Phase 2 Clinical Trial Of Its Investigational VX15/2503 Antibody In Huntington's Disease (The SIGNAL Trial) 6/24/2015
Baxalta Reports Continued Progress On Phase 1/2 Clinical Trial Of BAX335, Investigational Gene Therapy Treatment For Hemophilia B 6/24/2015
Acorda Therapeutics (ACOR) Data On Inhaled Levodopa Therapy CVT-301 Recognized In Blue Ribbon Highlights Session At International Congress Of Parkinson's Disease And Movement Disorders 6/24/2015
Spectrum Pharmaceuticals, Inc. (SPPI) Announces Publication Of Beleodaq Data Selected As A Rapid Communication In The Journal Of Clinical Oncology 6/24/2015
Evoke Pharma, Inc. Announces Publication of Clinical Data Demonstrating EVK-001 Significantly Improves Symptoms in Women With Diabetic Gastroparesis 6/24/2015
Zosano Pharma, Inc. Completes Enrollment In Phase 2 Trial For ZP-Glucagon, Its Microneedle Patch For Treatment Of Severe Hypoglycemia 6/23/2015
Cara Therapeutics, Inc. (CARA) Completes Enrollment Of Phase 2 Trial Of I.V. CR845 In Uremic Pruritus 6/23/2015
ObsEva Announces Recruitment Of The First Patient In TERM Phase 2 Study 6/23/2015
Helix Biopharma (TSX:HBP) Initiates Enrollment For Thirteenth Cohort In Polish Phase I/II Clinical Study Of Its Lung Cancer Drug Candidate L-DOS47 6/23/2015
BioMarin (BMRN) Surging on Impressive Phase II Dwarfism Data 6/22/2015
Vaxil BioTherapeutics's Lead Product Immucin Has Been Granted An Orphan Drug Designation By The FDA For The Treatment Of Multiple Myeloma 6/22/2015
Isis Pharma (ISIS) Reports Data From ISIS-SMN Rx In Children With Spinal Muscular Atrophy 6/22/2015
Investigator-Sponsored Trial Evaluating Biothera’s Imprime PGG In Relapsed Indolent Non-Hodgkin Lymphoma 6/22/2015
AOBiome Announces Start Of First Clinical Trial with Ammonia Oxidizing Bacteria-Based Therapeutic For Treatment Of Acne 6/22/2015
Tekmira (TKMR) Provides Update On TKM-Ebola-Guinea 6/19/2015
Burzynski Research Institute Announces Publication Of Phase II Results In Adults With Recurrent Anaplastic Astrocytoma 6/19/2015
Amgen (AMGN) Presents Open-Label Extension Data From Ongoing Phase 2 Study Of AMG 334 In The Prevention Of Episodic Migraine 6/19/2015
bluebird bio (BLUE) Surges as Pioneering Sickle Cell Gene Therapy Working for 13-Year-Old French Boy 6/18/2015
Analysts Question Avalanche Biotech (AAVL) Clinical Data, Could Jeopardize Regeneron (REGN) Deal 6/18/2015
Bay Area's Aimmune Wins FDA Breakthrough Therapy Designation for Allergy Drug 6/18/2015
StemCells (STEM)'s Phase II Pathway Study For Cervical Spinal Cord Injury Approved By Health Canada 6/18/2015
Galapagos (GLPG.BR) Completes Recruitment For ORIGIN Phase 2 Trial With GLPG1205 In Ulcerative Colitis Patients 6/18/2015
Akashi Therapeutics Reports Positive Clinical Data On HT-100 In Patients With Duchenne Muscular Dystrophy 6/18/2015
TG Therapeutics, Inc. (MHA) Release: Updated Results From Phase II Clinical Trial Of TG-1101 (Ublituximab) In Combination With Ibrutinib Confirms Robust Clinical Activity With A Favorable Safety Profile In Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL) 6/18/2015
Eli Lilly (LLY)'s Investigational Medicine For Prevention Of Migraine Met Primary Endpoint In A Phase 2b Study 6/17/2015
Astellas Pharma Inc. (ALPMY) And Medivation, Inc. (MDVN) Announce Enrollment Of The First Patients In Advanced Prostate Cancer Outcomes Registry 6/17/2015
Arrowhead Research Corporation (ARWR) Receives Regulatory Clearance To Begin Additional Phase 2b Studies Of Hepatitis B Candidate ARC-520 6/17/2015
Nordic Nanovector: Updated Results Of Ongoing Phase 1/2 Study With Betalutin In Relapsed CD37+ Non-Hodgkin Lymphoma Patients 6/17/2015
FDA's Office Of Orphan Products Development Issues Grant Supporting GenSpera Glioblastoma Study 6/17/2015
BiondVax Pharmaceuticals Announces FDA Acceptance Of IND Application For Its Investigational Universal Flu Vaccine 6/17/2015
Strategic Science & Technologies Initiates Phase II Study To Evaluate Topical Sildenafil In Men With Erectile Dysfunction 6/17/2015
Phase II Clinical Trial Featuring 22nd Century Group, Inc.'s Very Low Nicotine Tobacco Accepted For Publication 6/17/2015
Eli Lilly (LLY) Hits 14-Year High as Investors Await Alzheimer's Data 6/16/2015
Juventas Therapeutics, Inc. Granted FDA Fast Track Designation And Phase 2b Protocol Allowance For Novel Heart Failure Gene Therapy 6/16/2015
TONIX Pharmaceuticals, Inc. (TNXP) Initiates Phase II Clinical Study Of TNX-201 In Episodic Tension-Type Headache 6/16/2015
Akaal Pharma Receives Approval To Initiate Phase II Clinical Trial For The Topical Treatment Of Psoriasis 6/16/2015
Heron (HRTX) Initiates Phase II Clinical Trial Of HTX-011 For The Treatment Of Post-Operative Pain 6/16/2015
Teva (TEVA) Advances Pipeline Of Movement Disorder Assets With Announcement Of Positive Top-Line Data From The First Pivotal Study Of Investigational Treatment For Patients With Tardive Dyskinesia 6/16/2015
Avalanche Biotech (AAVL) Announces Positive Top-Line Phase IIa Results For AVA-101 In Wet Age-Related Macular Degeneration 6/16/2015
Pulmatrix Announces First Inhaled Anti-fungal Therapy For Cystic Fibrosis 6/16/2015
Clearside Biomedical Announces Favorable End-of-Phase 2 Review With The FDA 6/16/2015
Acetylon Pharmaceuticals Presented Positive Preliminary Data From Phase 1b/2 Trial Of Ricolinostat In Combination With Pomalyst As Potential Oral Treatment For Patients With Multiple Myeloma 6/16/2015
CTI BioPharma Release: Tosedostat In Combination With Low Dose Cytarabine Achieves Primary Endpoint In Phase 2 Study In Elderly Patients With AML 6/15/2015
BioLife Solutions, Inc. (BLFS.OB) CryoStor Cited In New Journal Article On Results Of Phase I/II Clinical Trial Of Dendritic Cell Immunotherapy For Prostate Cancer 6/15/2015
Juniper Pharmaceuticals Announces First Patient Enrolled In Phase II Study Of COL-1077 As An Acute-Use Anesthetic For Minimally-Invasive Gynecologic Procedures 6/15/2015
Apricus Biosciences (APRI) Announces Last Patient Enrolled In RayVa Phase IIa Clinical Trial For Raynaud's Phenomenon In Patients With Scleroderma 6/15/2015
Amarillo Biosciences (AMAR) Announces Presentation Of Eltoprazine Phase I/IIa Clinical Data At The 19th International Congress Of Parkinson's Disease And Movement Disorders 6/15/2015
Galena Biopharma  (GALE) Presents GALE-401 (Anagrelide Controlled Release) Phase II Data At The European Hematology Association 20th Congress 6/15/2015
BioLineRx Ltd. Presents Positive Safety And Efficacy Results For Novel Stem-Cell Mobilization Treatment At European Hematology Association Conference 6/15/2015
CTI BioPharma Release: Tosedostat In Combination With Low Dose Cytarabine Achieves Primary Endpoint In Phase 2 Study In Elderly Patients With AML 6/15/2015
XBiotech USA (XBIT) Announces Publication Of Phase II Clinical Results For Its True Human Antibody Mabp1 For Treating Acne Vulgaris 6/15/2015
Cytori Therapeutics, Inc. (CYTX) Completes Enrollment In US Phase IIb Osteoarthritis Trial 6/15/2015
Celgene (CELG) Release: Results From Analyses Of Revlimid MCL-002 (SPRINT) Study Presented At European Hematology Association 6/15/2015
Adamas Pharmaceuticals (ADMS) Announces Additional Findings From Its Phase II/III Trial Of ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) Associated With Parkinson's Disease 6/15/2015
Heat Biologics Announces Development Of Compact, A Next Generation Combination Immunotherapy Platform 6/15/2015
Acceleron Pharma Announces New Luspatercept Phase 2 Clinical Results At The 20th Congress Of The European Hematology Association 6/12/2015
Alnylam (ALNY) Reports Positive Initial Clinical Results For ALN-CC5, An Investigational RNAi Therapeutic Targeting Complement Component C5 For The Treatment Of Complement-Mediated Diseases 6/12/2015
Corbus Announces FDA Orphan Drug Designation For Resunab For The Treatment Of Systemic Sclerosis (Scleroderma) 6/12/2015
Seres Therapeutics' Lead Drug Granted a FDA Breakthrough Nod 6/12/2015
First Participant Dosed In Synthetic Biologics, Inc. (SYN)' Second Phase 2a Clinical Trial To Protect The Microbiome And Prevent C. difficile 6/12/2015
MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) (MSHL) Reports Updated Results From Phase II Study Of Pracinostat And Azacitidine In Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia 6/12/2015
Adamas Pharmaceuticals (ADMS) Begins Phase II Clinical Trial Assessing ADS-5102 For Treating Multiple Sclerosis Symptoms In Patients With Walking Impairment 6/12/2015
MediciNova, Inc. Announces Randomization Of 255 Subjects Completed In Phase IIb Trial Of MN-166 (Ibudilast) In Progressive MS 6/12/2015
ORYX' Oncolytic Virus ParvOryx Successfully Completes Phase I/IIa Trial To Treat Glioblastoma Multiforme 6/12/2015
Promedior Presents Additional Positive Phase 2 Data For PRM-151 In Myelofibrosis At EHA Annual Meeting 6/12/2015
Ariad (ARIA) Announces Long-Term Safety And Efficacy Data Of Ponatinib From Phase II Pace Clinical Trial 6/12/2015
bluebird bio (BLUE) Defies RAC Panel's Recommendation, Will Proceed With Two Planned Trials 6/11/2015
Isis Pharma (ISIS) Reports Data From ISIS-SMN Rx Phase 2 Study In Infants With Spinal Muscular Atrophy 6/11/2015
Tioga Pharmaceuticals Announces Initiation Of Phase 2 Clinical Study Of Asimadoline In Patients With Pruritus Associated With Atopic Dermatitis 6/11/2015
ForSight VISION5's Clinical Data Demonstrating 6-Month IOP-Lowering From A Single Dose Presented At World Glaucoma Congress; Company Completes Enrollment Of Phase 2 Dose-Ranging Study 6/11/2015
TONIX Pharmaceuticals, Inc. (TNXP) Presents Additional Data From Phase IIb BESTFIT Clinical Study At EULAR 6/11/2015
NeuroDerm (NDRM) Announces Start Of A Pharmacokinetic, Head-To-Head Comparison Study Of ND0612H And Duodopa 6/11/2015
Verona Pharma (VRP.L) Release: RPL554 Phase 2a Trial Started; Headline Data Expected Q1 2016 6/11/2015
ALK-Abello A/S's Partner, MSD, Publishes Phase II Data On House Dust Mite SLIT-Tablet In Leading Allergy Journal Journal 6/10/2015
Ziarco Initiates Phase IIa Clinical Trial Of ZPL-389 In Atopic Dermatitis 6/10/2015
Galapagos (GLPG.BR) DARWIN 1 And 2 Studies Have Completed 24 Weeks Of Treatment 6/10/2015
Novan Therapeutics Adds Clinical Exposure And Safety Data To SB204 Acne Program 6/10/2015
ALK’s Partner, Merck & Co. (MRK), Publishes Phase II Data On House Dust Mite SLIT-Tablet In Leading Allergy Journal 6/10/2015
bluebird bio (BLUE) Completes NIH RAC Review Of HGB-208 Pediatric Study Protocol 6/10/2015
Lion Biotechnologies, Inc. Receives Orphan Drug Designation For LN-144 For The Treatment Of Malignant Melanoma 6/10/2015
SAGE Therapeutics (SAGE) Soars as Postpartum Depression Disappears in Four New Mothers 6/10/2015
Nanobiotix Reports Positive Preliminary Results In Head And Neck Cancer Phase I/II Clinical Trial With NBTXR3 6/9/2015
RedHill Biopharma Ltd. (RDHL) Announces Completion Of Patient Enrollment In The Phase IIa Study Of RHB-104 For Multiple Sclerosis 6/9/2015
Dermira's Phase IIa DRM01 Acne Trial Data Presented At The World Congress Of Dermatology Meeting 6/9/2015
Stemedica Cell Technologies, Inc. Release: FDA Grants IND Approval For Phase Iia Clinical Trial Using Stemedica's itMSC Therapy To Treat Alzheimer's Disease 6/9/2015
SAGE Therapeutics (SAGE) Announces Positive Top-Line Data In Exploratory Trial Of SAGE-547 In Postpartum Depression 6/9/2015
Angion Biomedica Corp. To Commence Phase 2 Clinical Trial Of BB3 In Acute Kidney Injury 6/9/2015
Postive Trial Results Of Mesoblast (MSB.AX) Cell Therapy In Patients With Diabetes And Advanced Chronic Kidney Disease 6/9/2015
Nuvo Research Inc. (NRI.TO) Receives Health Canada Approval To Conduct New WF1 Phase 2 Trial 6/8/2015
Tobira Therapeutics Inc. Completes Patient Recruitment For CENTAUR Phase 2b Study Of Cenicriviroc In NASH With Liver Fibrosis 6/8/2015
Celator Pharmaceuticals, Inc. Announces Expansion of Clinical Study In Patients With Untreated Myelodysplastic Syndrome (MDS) Or Acute Myeloid Leukemia (AML) At High-Risk Of Treatment-Related Mortality 6/8/2015
Lipocine Inc. (LPCN) Announces Development Plans For LPCN 1107 6/8/2015
Aimmune's Peanut Allergy Drug Desensitizes Patients in Phase II Studyl 6/8/2015
Advaxis, Inc.'s Cancer Immunotherapy Delays Progression Of HER2+ Canine Osteosarcoma 6/8/2015
Asterias Biotherapeutics Announces First Patient Treated In Phase 1/2a Dose-Escalation Clinical Trial Of AST-OPC1 For Complete Cervical Spinal Cord Injury 6/8/2015
Aimmune Therapeutics Announces Positive Phase 2 Study Results Of AR101 For The Treatment Of Peanut Allergy 6/8/2015
Poxel’s Novel Anti-diabetic Agent Imeglimin Meets Glycemic Endpoints in Phase 2b Dose-Ranging Trial 6/8/2015
Hanmi Pharma: Efpeglenatide (GLP-1 Analog), The Promising Potential For Anti-Diabetes/Anti-Obesity Treatment As Once Weekly Up To Once Monthly 6/8/2015
Corbus Expands Clinical Development Of Resunab With A Phase 2 Trial For The Treatment Of Rare Disease Dermatomyositis 6/8/2015
vTv Therapeutics Initiates Patient Dosing In The AGATA Study, A Six Month Phase 2 Study Evaluating TTP399, A Liver-Selective Glucokinase Activator, For The Treatment Of Type 2 Diabetes 6/5/2015
First Patient Enrolled In Pivotal Therapeutics Inc.'s POMEGA Phase IIa Clinical Trial With PVT-100 6/5/2015
Synageva BioPharma (GEVA) Completes Targeted Enrollment In Phase 1/2 Trial With SBC-103 For Mucopolysaccharidosis IIIB 6/5/2015
Amarantus BioSciences, Inc. Opens First Clinical Trial Site And Commences Patient Enrollment For Lead Product Candidate Eltoprazine's Phase IIb Study In Parkinson's Disease Levodopa-Induced Dyskinesia 6/5/2015
Anthera Pharmaceuticals, Inc. (ANTH) Announces Additional Data On Patient-Reported Outcomes From Phase IIb PEARL-SC Blisibimod Study 6/5/2015
Cellular Biomedicine Group (CBMG) Announces Publication Of Human Adipose-Derived Progenitor Cells To Treat Knee Osteoarthritis 6/5/2015
Admedus HSV-2 Phase II Update: Patients Begin Receiving Second Dose 6/5/2015
Edge Therapeutics Receives FDA Orphan Drug Designation For EG-1962 For The Treatment Of Patients With Subarachnoid Hemorrhage 6/5/2015
Bay Area's Ardelyx (ARDX) Will Go It Alone on GI Drug As it Splits With AstraZeneca PLC (AZN) 6/4/2015
Flexion (FLXN)' Final FX006 Data From Completed Phase IIb Dose-Ranging Trial Published In Journal Of Bone And Joint Surgery 6/4/2015
StemCells (STEM) Announces Commencement Of The Second Cohort Of The Pathway Study In Cervical Spinal Cord Injury 6/4/2015
Promedior Announces Presentation Of Additional Positive Phase II Data On PRM-151 In Myelofibrosis At The Upcoming Congress Of The European Hematology Association 6/4/2015
Poxel Announces Additional Positive Phase 2 Results Establishing Unique Glucose-Control Features Of Imeglimin In Type 2 Diabetes 6/4/2015
Acucela Announces Publication Of Phase 2a Clinical Trial Results For Emixustat Hydrochloride 6/4/2015
Rhythm Initiates Two Phase 2 Clinical Trials Of Setmelanotide (RM-493) In Rare Genetic Disorders Of Obesity Caused By MC4 Pathway Deficiencies 6/4/2015
ASCO15 EXCLUSIVE: Experimental Brain Cancer Drugs Heads to Phase II/III Trial This Year: DelMar Pharmaceuticals CEO 6/3/2015
VaxInnate Corporation Advances Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, Into Phase II Study 6/3/2015
Aimmune Therapeutics To Announce Phase II Data At EAACI Congress 2015 For Study Of Peanut Allergy Desensitization Treatment 6/3/2015
Dezima Pharma's CETP Inhibitor, TA-8995, Phase IIb (TULIP) Study Results Published In The Lancet 6/3/2015
TapImmune Inc. (TPIV) Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 6/3/2015
Synthetic Biologics, Inc. (SYN) Presents Initial Data Validating Platform Expansion To Cover Carbapenem Antibiotics 6/3/2015
EIP Pharma Announces First Patient Dosing In Phase 2 Clinical Studies Of A Novel Brain-Targeted Anti-Inflammatory Drug Candidate, VX-745, For The Treatment Of Alzheimer's Disease (AD) 6/3/2015
Celator Pharmaceuticals, Inc. Announces Enrollment Is Complete In CPX-351 Phase 2 Study 6/3/2015
EXCLUSIVE: Nektar Therapeutics (NKTR), University of Texas MD Anderson Cancer Center Team Up on Phase 1/2 Trial of NKTR-214 6/2/2015
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: Clinical Trial Demonstrates Elevated Thymosin Beta 4 Plasma Levels Are Associated With Improvement Of Symptoms After Stem Cell Therapy In Patients With Ischemic Heart Failure 6/2/2015
ASCO15: Ascentia Pharma Inc. Release: New Enzalutamide Data In Triple-negative Breast Cancer Presented At The 2015 American Society Of Clinical Oncology Annual Meeting 6/2/2015
New Data On Lixisenatide (Lyxumia) Including ELIXA Results On Lixilan, And On Novel Zealand Pharma  (ZEAL.CO) Peptide Therapeutics, To Be Presented At The American Diabetes Association's 75th Scientific Sessions 6/2/2015
Viralytics Ltd (VLA.AX) Reports Positive Final Results From CAVATAKTM Phase 2 Melanoma Trial 6/2/2015
ASCO15: Oryx Pharmaceuticals Inc. Presents Positive Phase I/IIa Data With Therapeutic Vaccine MicOryx To Treat MSI-H Colorectal Cancers At ASCO 2015 6/2/2015
Positive Phase IIb Data On BM32, Biomay AG’s Innovative Grass Pollen Allergy Vaccine Will Be Reported Next Week In Hot Topic Session At Major International Scientific Conference 6/2/2015
ASCO15: Scancell Provides Positive Update On SCIB1 Data In Resected Melanoma Patients 6/2/2015
Ultragenyx Pharmaceuticals (RARE) Releases Positive 16-Week Interim Data From Pediatric Phase II Study Of KRN23 In X-Linked Hypophosphatemia 6/2/2015
ASCO15: Medivation, Inc. (MDVN) Release: New Enzalutamide Data In Triple-Negative Breast Cancer Presented At The 2015 American Society of Clinical Oncology Annual Meeting 6/2/2015
Synta (SNTA) Announces Ganetespib Program Updates 6/2/2015
ASCO15: Tiny Clovis Oncology (CLVS) Becomes an Even Bigger Takeover Target as Ovarian Cancer Drug Shrunk Tumors in 82% of Women 6/2/2015
ASCO15: Hope Rises As Celldex (CLDX)'s Brain Cancer Vaccine Helps Patients Live Longer 6/1/2015
ASCO15: DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data On VAL-083 In Refractory Glioblastoma Multiforme (GBM) At ASCO 6/1/2015
ASCO15: Array BioPharma, Inc. (ARRY) Release: Binimetinib And Encorafenib Combination Shows Promising Clinical Activity And Potential Differentiated Safety In BRAF-Mutant Melanoma 6/1/2015
ASCO15: Exelixis (EXEL) Results for Drug Combo Buoy the Flailing SF Biotech 6/1/2015
ASCO15: BioSpace (DHX)'s Roundup of What You May Have Missed at ASCO So Far 6/1/2015
Pharmacyclics (PCYC) Release: Ibrutinib (IMBRUVICA) Phase Ib/II Data Show Promise In Patients With Chronic Graft-Versus-Host-Disease 6/1/2015
ASCO15: Clovis Oncology (CLVS)’s Rociletinib (CO-1686) Phase II Study Results Demonstrate Consistent And Promising Clinical Activity And Disease Control In Very Advanced Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC 6/1/2015
ASCO15: AbbVie (ABBV) Presents Phase 2 Results From Study Of Investigational Medicine Veliparib In Patients With Non-Small Cell Lung Cancer At The American Society Of Clinical Oncology Annual Meeting 6/1/2015
Janssen Research & Development Release: Data Show Daratumumab Achieved a Pronounced Overall Response Rate As A Single-Agent With Tolerable Safety Profile In Heavily Pre-Treated Multiple Myeloma Patients 6/1/2015
ASCO15: Results From Phase 2 Study Of Lenvatinib When Combined With Everolimus In Metastatic Renal Cell Carcinoma To Be Presented In Oral Session At ASCO 6/1/2015
ASCO15: Esperance Pharmaceuticals, Inc. Reports Positive EP-100 Phase Ll Results In Ovarian Cancer At 2015 ASCO Annual Meeting 6/1/2015
Mirati Therapeutics  (MRTX) Release: Initial Data From Ongoing Expansion Study Of MGCD265 Show Preliminary Evidence Of Clinical Efficacy In Heavily Pretreated Non-Small Cell Lung Cancer (NSCLC) Patients With MET Gene Alterations 6/1/2015
Astellas Pharma Inc. (ALPMY) Announces Preliminary Phase 1/2 Safety, Tolerability And Efficacy Data For ASP2215 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML) 6/1/2015
ASCO15: Novartis AG (NVS) Presents New Data At ASCO For Zykadia And Combination Of Tafinlar And Mekinist In Certain NSCLC Patients With Unmet Needs 6/1/2015
Positive New, Long-Term Follow-Up Data Of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival In Patients With High-Risk Acute Myelogenous Leukemia (AML) 6/1/2015
ASCO15: TRACON Pharmaceuticals, Inc. (TCON) Announces Positive Results Of TRC105 Clinical Trials In Sarcoma And Liver Cancer At The ASCO 2015 Annual Meeting 6/1/2015
Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations And Confirms Tumor Heterogeneity In High-Grade Glioma Samples 6/1/2015
Peregrine Pharmaceuticals, Inc. (PPHM) Provides Update On Planned Expansion Of Bavituximab Clinical Program 6/1/2015
ASCO15: VBL Therapeutics (VBLX) Reports Updated Interim Results From Phase II Clinical Trial Of VB-111 In Recurrent Glioblastoma (Rgbm) 6/1/2015
ASCO15: AstraZeneca PLC (AZN) And MedImmune (AZN) Present Positive Immuno-Oncology Combination Data At ASCO 2015 6/1/2015
ASCO15: Celldex (CLDX) Release: Randomized Phase 2 React Study Of RINTEGA In Recurrent Bevacizumab-Naive Glioblastoma Demonstrates Statistically Significant Overall Survival And Emergence Of Long-Term Survival Benefit; Primary Endpoint Of PFS6 Met 6/1/2015
Apricus Biosciences (APRI) Enrolls First Patients In Phase IIb Clinical Trial For Fispemifene In Men With Symptomatic Secondary Hypogonadism 6/1/2015
Exelixis (EXEL) Announces Positive Results From Phase 2 Investigator-Sponsored Trial Of Cabozantinib In RET-Rearranged Non-Small Cell Lung Cancers 6/1/2015
Exelixis (EXEL) Announces Positive Results From Phase 2 Trial Of Cabozantinib In Patients With EGFR Wild-Type Non-Small Cell Lung Cancer 6/1/2015
Merck & Co. (MRK)’s MK-2206 "Graduates" From I-SPY 2 Breast Cancer Trial Showing Benefit For HER2+ And Hormone-Receptor Negative Breast Cancer 6/1/2015
DNA Therapeutics Presents Encouraging Results For First-In-Class Pan DNA Repair Inhibitor 6/1/2015
Roche (RHHBY)’s Perjeta Regimen Helped People With HER2-Positive Early Breast Cancer Live Longer Without Their Disease Returning Or Getting Worse Compared To Herceptin And Chemotherapy 6/1/2015
Pharming Group (PHGUF.PK) Announces Interim Results From The Ongoing Phase II Pediatric Clinical Trial Of Ruconest 6/1/2015
BioLineRx Ltd. Announces Peer-Reviewed Publication Of Phase 1/2 Trial Results For Novel Treatment For Non-Surgical Removal Of Skin Lesions 6/1/2015
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Data From Borealis-1 Trial Showing Clinical Benefit With Apatorsen In Metastatic Bladder Cancer 6/1/2015
ASCO15: Karyopharm (KPTI) Presents Clinical Data For Selinexor (KPT-330) In Patients With Heavily Pretreated Gynecological Cancers And Asian Patients With Advanced Malignancies At 2015 ASCO Annual Meeting 6/1/2015
ASCO15: Seattle Genetics (SGEN) Highlights ADCETRIS® (Brentuximab Vedotin) Data Presentations In The AETHERA Post-Transplant Consolidation Setting And In Frontline DLBCL At ASCO Annual Meeting 6/1/2015
ASCO15: Agenus (AGEN) Release: Updated Phase 2 Data Of Prophage In Newly Diagnosed GBM Presented At ASCO Show Improvement In Median Progression Free Survival And Overall Survival Independently Of Prognostic Markers, Compared With Historical Expectations 6/1/2015



//-->